Psyched Wellness (CSE: PSYC) continues to execute on its strategy as it pertains to the amanita muscaria mushroom. The company, through its contract research organization, KGK Science, has now begun the next pre-clinical trial study on its proprietary extract, referred to as AME-1.
The next round of pre-clinical trials focuses on the beneficial or adverse health extracts of the compound, with the trial referred to as a conditioned placement preference study. The study itself reportedly works by comparing characteristics of the association of the extract in an environment, to the association in another environment without the extract.
Effectively, the study will look into whether the compound developed by Psyched has any abuse potential. The trial is a means of determining whether psychological or physical dependence of the substance can be formed around the extract.
Sponsored · Antimony Resources
“In conjunction with the other studies the Company is conducting, this trial will bolster Psyched’s toxicological assessment of AME-1 and provide critical knowledge of any behavioral and neurological functional changes in a scientific setting. This is another key step in determining a safe dose of AME-1 for human consumption and moves Psyched closer to being able to bring our Amanita-based CPG products to market,” commented David Shisel, COO of Psyched Wellness.
Psyched Wellness last traded at $0.135 on the CSE.
FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
